CES1 Crossover Trial of Clopidogrel and Ticagrelor
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this investigation is to evaluate when genetic variation in the
carboxylesterase 1 (CES1) gene influences antiplatelet therapy response, as assessed by ex
vivo platelet aggregometry, in healthy participants treated with clopidogrel and ticagrelor.
We hypothesize that genetic variation in CES1 will significantly impact on-clopidogrel
platelet aggregation while having a minimal effect in ticagrelor-treated subjects.
Specific Aim: To conduct a prospective randomized crossover study of clopidogrel and
ticagrelor in healthy individuals stratified by CES1 genotype. Participants will be recruited
by CES1 genotype into a randomized crossover study of clopidogrel (75 mg daily for 7d) and
ticagrelor (90 mg twice daily for 7d) with extensive phenotyping including ex vivo platelet
aggregometry performed pre- and post-drug administration in order to assess the interaction
of genotype and drug choice on on-treatment platelet function.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore